Allergan PLC Company Profile (NYSE:AGN)

About Allergan PLC

Allergan PLC logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: AGN
  • CUSIP: 01849010
Key Metrics:
  • Previous Close: $225.29
  • 50 Day Moving Average: $236.29
  • 200 Day Moving Average: $236.25
  • 52-Week Range: $195.50 - $322.68
  • Trailing P/E Ratio: 21.45
  • Foreward P/E Ratio: 13.29
  • P/E Growth: 1.22
  • Market Cap: $89.20B
  • Outstanding Shares: 395,952,000
  • Beta: 0.81
  • Net Margins: 28.06%
  • Return on Equity: 7.67%
  • Return on Assets: 4.04%
  • Debt-to-Equity Ratio: 0.52%
  • Current Ratio: 0.99%
  • Quick Ratio: 0.91%
Additional Links:
Companies Related to Allergan PLC:

Analyst Ratings

Consensus Ratings for Allergan PLC (NYSE:AGN) (?)
Ratings Breakdown: 5 Hold Ratings, 18 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $304.42 (35.12% upside)

Analysts' Ratings History for Allergan PLC (NYSE:AGN)
DateFirmActionRatingPrice TargetDetails
10/15/2016Deutsche Bank AGSet Price TargetBuy$278.00View Rating Details
10/11/2016MizuhoLower Price TargetBuy$305.00 -> $299.00View Rating Details
10/4/2016ArgusReiterated RatingBuy$340.00View Rating Details
9/27/2016Goldman Sachs Group Inc.Reiterated RatingBuy$300.00View Rating Details
9/20/2016Bank of America Corp.Set Price TargetBuy$294.00View Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details
8/30/2016Piper Jaffray Cos.Reiterated RatingNeutral$227.00View Rating Details
8/10/2016RBC Capital MarketsReiterated RatingOutperform$307.00 -> $300.00View Rating Details
8/8/2016Leerink SwannSet Price TargetBuy$294.00View Rating Details
8/9/2016Royal Bank Of CanadaLower Price TargetOutperform$307.00 -> $300.00View Rating Details
8/5/2016JPMorgan Chase & Co.Set Price TargetBuy$325.00View Rating Details
8/3/2016Credit Suisse Group AGSet Price TargetHold$322.00View Rating Details
6/29/2016Morgan StanleyReiterated RatingOverweightView Rating Details
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
6/9/2016Sanford C. BernsteinReiterated RatingOutperform$335.00View Rating Details
5/29/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
4/7/2016Raymond James Financial Inc.Lower Price TargetOutperform$317.00 -> $275.00View Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyView Rating Details
4/7/2016SusquehannaDowngradePositive -> Neutral$345.00 -> $275.00View Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00View Rating Details
7/29/2015Barclays PLCReiterated RatingHoldView Rating Details
6/20/2015BMO Capital MarketsSet Price TargetBuy$378.00View Rating Details
1/8/2015BTIG ResearchDowngradeBuy -> NeutralView Rating Details
12/15/2014Stifel NicolausDowngradeBuy -> Hold$200.00View Rating Details
11/18/2014Jefferies GroupReiterated RatingHold$184.00 -> $219.00View Rating Details
11/18/2014SunTrust Banks Inc.DowngradeBuy -> NeutralView Rating Details
11/18/2014William BlairDowngradeOutperform -> Market Perform$219.00View Rating Details
(Data available from 10/26/2014 forward)


Earnings History for Allergan PLC (NYSE:AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016ListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.18$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.38$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
2/4/2015Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
10/27/2014Q314$1.68$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
5/7/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan PLC (NYSE:AGN)
Current Year EPS Consensus Estimate: $13.95 EPS
Next Year EPS Consensus Estimate: $16.95 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$2.91$3.17$3.04
Q2 20161$3.29$3.29$3.29
Q3 20161$3.55$3.55$3.55
Q4 20161$4.10$4.10$4.10
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan PLC (NYSE:AGN)
Annual Dividend:$0.00
Dividend Yield:0.00%
Dividend Growth:-37.00% (3 Year Average)
Payout Ratio:0.00% (Based on Trailing 12 Months of Earnings)
0.00% (Based on Current Year Consensus EPS Estimate)
0.00% (Based on Next Year Consensus EPS Estimate)

Dividend History for Allergan PLC (NYSE:AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Allergan PLC (NYSE:AGN)
Insider Ownership Percentage: 0.27%
Institutional Ownership Percentage: 85.30%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Allergan PLC (NYSE:AGN)
News IconNewsmaking Penny Stock: Investors Checking Out Allergan plc (NYSE:AGN) - Duncan Research (NYSE:AGN) - October 25 at 3:24 PM
News IconAllergan plc (NYSE:AGN) earnings expectations - The Independent Republic (NYSE:AGN) - October 25 at 3:24 PM
News IconNgam Advisors LP invests in Allergan PLC (AGN) Shares - DailyQuint (NYSE:AGN) - October 25 at 3:24 PM
News IconLarge Cap Drugs – Generic: Allergan plc (NYSE:AGN) (NYSE:AGN) - October 25 at 8:12 AM logoAllergan Successfully Completes Vitae Tender Offer (NYSE:AGN) - October 25 at 8:12 AM
News IconAllergan plc (NYSE:AGN) Analysts Recommendations and Insider Trading - The Independent Republic (NYSE:AGN) - October 24 at 3:24 PM logoAstraZeneca : Allergan to Present New Data from its Anti-Infectives Portfolio at IDWeek 2016 in New Orleans (NYSE:AGN) - October 24 at 8:11 AM logoAllergan to Present New Data from its Anti-Infectives Portfolio at IDWeek 2016 in New Orleans (NYSE:AGN) - October 24 at 8:11 AM logo[$$] Allergan's Upside: 20%-30% (NYSE:AGN) - October 22 at 7:44 AM
News IconMoody Lynn & Lieberson LLC Acquires 1178 Shares of Allergan PLC (AGN) - DailyQuint (NYSE:AGN) - October 21 at 8:25 PM logoStocks To Track: Allergan plc (AGN), Helix Energy Solutions Group, Inc. (HLX), Rice Energy Inc. (RICE) - iStreetWire (NYSE:AGN) - October 21 at 3:22 PM
News IconAllergan plc's (AGN): Investor's Alert - Hot Stocks Point (NYSE:AGN) - October 21 at 3:22 PM
News IconAllergan plc (NYSE:AGN) from Drugs – Generic – Todays Top Gains (NYSE:AGN) - October 21 at 12:33 PM logoGilead NASH Drug 'Active And Promising,' But Lagging Intercept (NYSE:AGN) - October 21 at 12:33 PM
News IconAllergan plc (NYSE:AGN) – Top Stock from Healthcare Sector - The Daily Leicester (NYSE:AGN) - October 20 at 3:44 PM logoAllergan (AGN) Affirms Receipt of FDA Committee Backing for Desmopressin Nasal Spray NDA - (NYSE:AGN) - October 20 at 3:44 PM logoFDA Advisory Committee Recommends Approval of SER120 (desmopressin nasal spray) (NYSE:AGN) - October 20 at 3:44 PM logoAllergan (AGN) Announces U.S. Launch of JUVÉDERM VOLBELLA XC (NYSE:AGN) - October 20 at 9:13 AM
News IconIs Allergan (AGN) Still an Undervalued Stock? (NYSE:AGN) - October 20 at 9:13 AM
News IconDrugs – Generic: Allergan plc (NYSE:AGN) Position of the day (NYSE:AGN) - October 20 at 9:13 AM logoFDA panel backs Allergan's drug for frequent nightly urination (NYSE:AGN) - October 20 at 9:13 AM
News IconThe Statistics Don't Lie: Allergan plc (AGN) Earnings Preview - The Voice Registrar (NYSE:AGN) - October 19 at 4:11 PM
News IconTrader's Radar- Allergan plc's (AGN) - Hot Stocks Point (NYSE:AGN) - October 19 at 4:11 PM logoBRIEF-Allergan, Tobira Therapeutics say waiting period terminated for proposed merger (NYSE:AGN) - October 19 at 9:10 AM logoWhat's Ailing Allergan's Share Price - Seeking Alpha (NYSE:AGN) - October 19 at 8:13 AM logoAllergan and Tobira Therapeutics Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Proposed Acquisition of Tobira (NYSE:AGN) - October 19 at 8:13 AM logoEli Lilly’s 3Q16 Estimates: Expect Revenue Growth! (NYSE:AGN) - October 19 at 8:13 AM
News IconStocks in the News: Allergan plc Ordinary Shares (NYSE:AGN), Gulfport Energy Corporation (NASDAQ:GPOR) - NYSE Journal (press release) (NYSE:AGN) - October 18 at 3:23 PM logoJUVÉDERM VOLBELLA® XC Now Available To Doctors And Patients In The U.S. (NYSE:AGN) - October 18 at 3:23 PM logoInvestor's Watch List: Allergan plc (AGN), FireEye, Inc. (FEYE), The Goodyear Tire & Rubber Company (GT) - iStreetWire (NYSE:AGN) - October 18 at 8:08 AM
News Icon2 Stocks Analyst-Opinion Need Close Attention: Allergan plc (NYSE:AGN), Sprint Corporation (NYSE:S) - The Voice Registrar (NYSE:AGN) - October 18 at 8:08 AM
News IconRoberts Glore & Co. Inc. IL Acquires New Stake in Allergan PLC (AGN) - DailyQuint (NYSE:AGN) - October 18 at 8:08 AM
News IconAllergan PLC (AGN) PT Lowered to $299.00 - DailyQuint (NYSE:AGN) - October 18 at 8:08 AM logoAllergan (AGN) Forms New IBS CounSEL - - (NYSE:AGN) - October 17 at 3:21 PM logoBRIEF-Allergan, Vitae Pharmaceuticals announce expiration of HSR waiting period (NYSE:AGN) - October 17 at 11:52 AM logoAllergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine … (NYSE:AGN) - October 17 at 8:11 AM logoAllergan's Belkyra Gets Swedish Approval for Double Chin (NYSE:AGN) - October 17 at 8:11 AM logoDeutsche Bank Trims Estimates For Three Healthcare Giants: Valeant Pharmaceuticals Intl Inc (VRX), Teva Pharmaceutical (TEVA) and Allergan plc (AGN) (NYSE:AGN) - October 16 at 8:10 AM
News IconLeading stocks in today’s market: Allergan plc (NYSE:AGN) (NYSE:AGN) - October 16 at 8:10 AM logoAllergan Demonstrates Ongoing Commitment to Irritable Bowel Syndrome (IBS) with Development of IBS CounSEL (NYSE:AGN) - October 16 at 8:10 AM
News IconFitbit Inc (NYSE:FIT) & Allergan plc Ordinary Shares (NYSE:AGN ... - Money News (NYSE:AGN) - October 15 at 3:21 PM
News IconBbva Compass Bancshares Inc. decides to keep it stake in Allergan PLC (AGN) to the level of $2649000 - DailyQuint (NYSE:AGN) - October 15 at 8:11 AM
News IconEarnings Reaction History: Allergan plc (NYSE:AGN) has a 65.38% chance to decline - The Independent Republic (NYSE:AGN) - October 14 at 3:22 PM logoShire Routs Incumbent Allergan In Booming Dry-Eye Market: RBC (NYSE:AGN) - October 14 at 3:22 PM logoNo, Virginia, the M&A market has not gone into a death spiral (NYSE:AGN) - October 14 at 3:22 PM logoAllergan (AGN) to Present IBS Portfolio Data at ACG Annual Meeting - (NYSE:AGN) - October 14 at 11:54 AM
News IconConsensus Judgments in Focus About- Allergan plc (NYSE:AGN), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) - Seneca Globe (NYSE:AGN) - October 14 at 11:54 AM logoAllergan (AGN) Licenceses RTGel Rights from UroGen Pharma - (NYSE:AGN) - October 14 at 11:54 AM logoAllergan Demonstrates Continued Commitment to Irritable Bowel Syndrome with Diarrhea Management with Two Poster Presentations at ACG 2016 (NYSE:AGN) - October 14 at 11:54 AM logoAllergan (AGN) Announces Receipt of Marketing Approval in ... - (NYSE:AGN) - October 13 at 8:42 PM


Allergan PLC (NYSE:AGN) Chart for Wednesday, October, 26, 2016

Last Updated on 10/26/2016 by Staff